Boston Scientific’ WATCHMAN FLX Pro Left Atrial Appendage Closure Device Receives the US FDA Approval for Non-Valvular Atrial Fibrillation
- The US FDA has approved the latest-generation WATCHMAN FLX Pro LAAC device to reduce stroke risk in patients with NVAF who need an alternative to oral anticoagulation therapy. The device features a polymer coating, visualization markers & a broader size matrix to treat a wider range of patients
- The device is currently being studied in the (WATCHMAN FLX Pro CT) premarket study using multiple imaging modalities to evaluate post-procedural device tissue coverage & will also be assessed in the post-market (HEAL-LAA) study which is expected to be initiated over the coming weeks
- This device is designed to enhance post-procedural healing, improve the precision of WATCHMAN FLX Pro implants, and expand the size range of treatable appendages, available in a new 40mm size option
Ref: PRNewswire | Image: Boston Scientific
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.